Core Viewpoint - BlackBerry Limited's stock declined despite beating third-quarter earnings and revenue expectations, as investor focus shifted to concerns over slowing QNX growth, overshadowing strong profitability and Secure Communications performance [1]. Financial Performance - BlackBerry reported third-quarter revenue of $141.8 million, exceeding analyst estimates of $137.4 million [2]. - The company achieved adjusted earnings of 5 cents per share, surpassing estimates of 4 cents per share [2]. - Fiscal 2026 revenue guidance was raised to a range of $531 to $541 million, compared to estimates of $531.94 million [3]. Analyst Insights - RBC Capital Markets analyst Paul Treiber maintained a Sector Perform rating with a price forecast of $4.50, noting that the third-quarter results exceeded both the firm's and consensus expectations [4]. - The revenue beat was primarily attributed to one-time revenue in the Secure Communications segment rather than sustained momentum in QNX [4]. QNX Performance - QNX revenue increased by 10% year over year, but it fell slightly short of expectations and showed a slowdown from the previous quarter's growth rate [5]. - Fourth-quarter guidance indicates a deceleration in QNX's year-over-year growth, suggesting a lower growth trajectory despite easier comparisons [5]. - BlackBerry narrowed its fiscal 2026 QNX revenue outlook, with weakened investor visibility into QNX growth, as a significant portion of recent growth was linked to Radar rather than core demand [5]. Stock Performance - BlackBerry shares were down 11.09% at $3.845 at the time of publication [6].

Core Viewpoint - Pfizer (PFE.US) shares fell over 4% to $25.27 as the company forecasts minimal or no sales growth for the upcoming year due to efforts to revamp its drug portfolio through expensive acquisitions [1] Group 1: Financial Projections - Pfizer expects revenue for 2026 to be between $59.5 billion and $62.5 billion, aligning with Wall Street expectations [1] - The company anticipates 2023 sales to be approximately $62 billion, consistent with its guidance from early November [1] - Adjusted earnings per share for the next year are projected to be between $2.80 and $3.00 [1] Group 2: Market Challenges - CEO Albert Bourla is facing a critical moment in revitalizing Pfizer as the demand for COVID-19 vaccines and treatments, which previously drove sales growth, is declining [1] - Revenue from COVID-related products is expected to decrease by approximately $1.5 billion to $5 billion next year [1]

Core Viewpoint - Pfizer (PFE.US) shares fell over 4% to $25.27 as the company forecasts minimal or no sales growth for the upcoming year due to expensive acquisitions aimed at updating its popular drug lineup [1] Financial Projections - Pfizer expects revenue for 2026 to be between $59.5 billion and $62.5 billion, aligning with Wall Street expectations [1] - The company anticipates this year's sales to reach $62 billion, consistent with its guidance from early November [1] - Adjusted earnings per share for next year are projected to be between $2.80 and $3.00 [1] Market Challenges - CEO Albert Bourla faces a critical moment in revitalizing Pfizer as demand for COVID-19 vaccines and treatments, which previously drove sales growth, is declining [1] - Revenue from COVID-related products is expected to decrease by approximately $1.5 billion to $5 billion next year [1]

Core Viewpoint - Su Nong Bank has appointed Wang Liang as the new president following the resignation of Zhang Yingjie due to work changes, with the new management team facing challenges related to narrowing interest margins and slowing revenue growth [1][4]. Financial Performance - For the first three quarters of 2025, Su Nong Bank reported operating income of 3.221 billion yuan, a year-on-year increase of 0.08%, and a net profit attributable to shareholders of 1.708 billion yuan, up 5.01% year-on-year [1]. - The bank's net interest income decreased from 2.14 billion yuan in the same period last year to 2.058 billion yuan due to a narrowing net interest margin [1][2]. - The net interest margin for the first three quarters of 2025 was reported at 1.33%, down from 1.55% in 2024 and 1.74% in 2023 [4]. Loan and Credit Growth - As of mid-2025, Su Nong Bank's loan balance reached 136.331 billion yuan, an increase of 6.997 billion yuan or 5.41% from the beginning of the year [3]. - The bank aims to continue supporting small and micro enterprises while optimizing the structure of fund supply and focusing on key areas such as rural revitalization, advanced manufacturing, green development, and technological innovation [3]. Management Changes - Wang Liang, previously the deputy secretary of the party committee at Su Nong Bank, has taken over as acting president pending regulatory approval [1][4]. - The departure of the former president is not expected to disrupt the normal operations of the board or the management of the bank [4].

Core Viewpoint - Duolingo's stock is experiencing a significant decline despite reporting strong third-quarter earnings, primarily due to weaker-than-expected forward guidance and a strategic shift [2][7]. Financial Performance - Duolingo reported earnings per share of $5.95 on sales of $271.7 million for Q3, exceeding analyst expectations of $0.76 EPS and $260.35 million in sales [4]. - Revenue for the quarter was approximately 41% higher than the same period last year, with the company surpassing 50 million daily active users [5]. Guidance and Market Reaction - For Q4, Duolingo expects sales between $273 million and $277 million, which is above the average analyst target of $274.4 million [6]. - However, the company's guidance for bookings between $329.5 million and $335.5 million fell short of the average estimate of $344.1 million, indicating potential challenges ahead [6][8]. - The stock price dropped 26% during trading, reflecting a broader market decline and a significant valuation pullback following the Q3 results [1][2].

Core Viewpoint - New Oriental Education & Technology Group (09901) reported a mixed financial performance, with revenue growth but a significant decline in net profit, leading to a decrease in stock price [1] Financial Performance - For the fourth quarter of fiscal year 2025, New Oriental's net revenue increased by 9.4% year-on-year to $1.243 billion [1] - The net profit for the same period fell by 73.7% year-on-year to $7.1 million [1] Future Guidance - For the first quarter of fiscal year 2026 (June 1, 2025, to August 31, 2025), New Oriental expects net revenue to be between $1.464 billion and $1.507 billion, reflecting a year-on-year growth rate of 2% to 5% [1] - For the entire fiscal year 2026 (June 1, 2025, to May 31, 2026), the company projects net revenue to be between $5.145 billion and $5.39 billion, indicating a year-on-year growth rate of 5% to 10% [1] Analyst Insights - Bank of America noted that the revenue guidance for the first quarter and full fiscal year 2026 reflects a slowdown in overseas business and K9 subject training growth [1] - Morgan Stanley highlighted that while the fourth quarter results exceeded expectations, the revenue guidance for the first quarter and full year 2026 fell short of market expectations, raising concerns about the potential impact of deteriorating overseas demand on revenue and profit margins [1]